AEON BIOPHARMA INC (AEON) Stock Price, Quote, News and Overview
NYSEARCA:AEON - NYSE Arca - US00791X1000 - Common Stock - Currency: USD
AEON Quote, Performance and Key Statistics
AEON BIOPHARMA INC
NYSEARCA:AEON (2/7/2025, 8:10:36 PM)
After market: 0.1269 0 (-2.61%)0.1303
-0.01 (-6.93%)
The current stock price of AEON is 0.1303 USD. In the past month the price decreased by -31.46%. In the past year, price decreased by -98.55%.
AEON Latest News and Analysis
Wondering what's happening in today's after-hours session?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Top movers in Monday's after hours session
Monday's after hours session: top gainers and losers
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused...
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why
Cancer treatments, FDA breakthroughs, and other developments fueled a sharp spike in interest for these biotech players, as investors bet on promising clinical data and strategic moves.
About AEON
Company Profile
AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.
Company Info
AEON BIOPHARMA INC
4040 Macarthur Boulevard, Suite 310
Newport Beach CALIFORNIA US
Employees: 5
Company Website: https://www.aeonbiopharma.com/
Investor Relations: https://investors.aeonbiopharma.com/overview/default.aspx
Phone: 19492844555.0
AEON FAQ
What is the stock price of AEON?
The current stock price of AEON is 0.1303 USD.
What is the symbol for AEON BIOPHARMA INC stock?
The exchange symbol of AEON BIOPHARMA INC is AEON and it is listed on the NYSE Arca exchange.
On which exchange is AEON stock listed?
AEON stock is listed on the NYSE Arca exchange.
Is AEON a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AEON, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AEON.
Does AEON stock pay dividends?
AEON does not pay a dividend.
What is the Price/Earnings (PE) ratio of AEON?
AEON does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).
What is the Short Interest ratio of AEON stock?
The outstanding short interest for AEON is 10.94% of its float.
AEON Technical Analysis
AEON Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AEON. Both the profitability and financial health of AEON have multiple concerns.
AEON Financial Highlights
Over the last trailing twelve months AEON reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS decreased by -409.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -116.07% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AEON Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to AEON. The Buy consensus is the average rating of analysts ratings from 7 analysts.